机构:[1]Key Laboratory of AnimalModels and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China[2]University of Chinese Academy of Sciences, Beijing 100009, China[3]State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[4]The Department of dermatology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China昆明医科大学附属第一医院[5]The Department of Pathology, The Affiliated Hospital of Jiangnan University Wuxi 4th People's Hospital, Wuxi 214062, Jiangsu, China[6]Department of Physiology and Membrane Biology, University of California, Davis, California 95616, United States[7]Life Sciences College of Nanjing Agricultural University, Nanjing 210095, Jiangsu, China
Psoriasis is histologically characterized by keratinocytes (KC) hyperproliferation, inflammation, and increased angiogenesis, but the pathological factor responsible for these symptoms is unknown. Here, a neuroendocrine peptide (prokineticin 2, PK2), is highly expressed in human and mouse psoriatic skins but no significant change in other autoimmune diseases, suggesting that PK2 is a psoriasis-specific factor. Bacterial products significantly up-regulated PK2, implying that infection induces PK2 over-expression. PK2 promoted KC and macrophage to produce interleukin-1 (IL-1), the central player of inflammation and psoriasis, which acts on adjacent fibroblast to induce inflammatory cascades and KC hyperproliferation. IL-1 feeds back on macrophages to induce PK2 production to perpetuate PK2-IL-1 positive feedback loop. PK2 also promoted angiogenesis, another psoriatic symptom. In mouse models, PK2 over-expression aggravated psoriasis while its knock-down inhibited pathological development. The results indicate that PK2 over-production perpetuates psoriatic symptoms by creating PK-2-IL-1 vicious loop. PK2 is a central player in psoriasis and a promising psoriasis-specific target. (C) 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
基金:
NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072377]
第一作者机构:[1]Key Laboratory of AnimalModels and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China
共同第一作者:
通讯作者:
通讯机构:[1]Key Laboratory of AnimalModels and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China[*1]Kunming Institute of Zoology, Chinese Academy of Sciences, 650223 Kunming, Yunnan, China.
推荐引用方式(GB/T 7714):
He Xiaoqin,Shen Chuanbin,Lu Qiumin,et al.Prokineticin 2 Plays a Pivotal Role in Psoriasis[J].EBIOMEDICINE.2016,13:248-261.doi:10.1016/j.ebiom.2016.10.022.
APA:
He, Xiaoqin,Shen, Chuanbin,Lu, Qiumin,Li, Jiong,Wei, Yuquan...&Lai, Ren.(2016).Prokineticin 2 Plays a Pivotal Role in Psoriasis.EBIOMEDICINE,13,
MLA:
He, Xiaoqin,et al."Prokineticin 2 Plays a Pivotal Role in Psoriasis".EBIOMEDICINE 13.(2016):248-261